Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
45. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165: 335—8.
46. Rothe G, Herr AS, Stohr J, Abletshauser C, Weidinger G, Schmitz G. A more mature pheno-type of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999; 144: 251—61.
47. Ganne F, Vasse M, Beaudeux JL, et al. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins-con-sequences for plasmin generation and monocyte adhesion. Thromb Haemost 1999; 81: 594— 600.
48. Ganne F, Vasse M, Beaudeux JL, et al. Ceri-vastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood mono-cytes-a possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84: 680—8.
49. Kreuzer J, Bader J, Jahn L, Hautmann M, Kubler W, Von Hodenberg E. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203—9.
50. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80:1095—100.
51. Kim SY, Guijarro C, ODonnell MP, Kasi-ske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant pro-tein-1: modulation by lovastatin. Kidney Int 1995; 48: 363—71.
52. Sumi D, Hayashi T, Thakur NK, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid
SHS-OOO4.qxd 21.11.2006 16:56 Page 431
ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома
lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion cavenging action. Atherosclerosis 2001; 155: 347—57.
53. Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 122—8.
54. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-
I levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48: 183—9.
55. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998; 31: 773—8.
56. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993; 13: 571—578.
57. Yasunari K, Maeda K, Minami M, Yoshi-kawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001; 21: 937—942.
58. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000 Dec; 6: 1399—1402.
59. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class
II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106—109.
60. Palinski W. Immunomodulation: a new role for statins? Nature Med 2000; 12: 1311—2.
61. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983—4.
62. Grip O, Janciauskiene S, Lindgren S. Pra-vastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410: 83—92.
63. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti-inflammatory effects of simvastatin in subjects with hypercholes-terolemia. Int J Cardiol. 2001; 77: 247—53.
64. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, et al. The HMG-Co A reductase inhibitor, ator-vastatin, promotes a Th2 bias and reverses paral-
ysis in central nervous system autoimmune disease. Nature 2002; 420: 78—84.
65. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621—7.
66. Wenke K, Meiser B, Thiery J, et al. Simva-statin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398—402.
67. Bustos C, Hernandez-Presa MA, Ortego M. et al. HMG-CoA reductase inhibition by atorvas-tatin redues neointimal inflammation in a rabbit model of atherosclerosis. JAm Coll Cardiol 1998; 32: 2057—64.
68. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbel C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory tole for simvastatin in inflammatory atthritis. J Immunol 2003; 170: 1524—1530.
69. Kanda H, Hamasaki K, Kubo K, et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatology 2003;
70. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839—44.
